In a Collective Evolution article Robert F. Kennedy Jr reported that that out of the 16 HPV vaccine randomized trials only two used an inert saline placebo. Ten of the trials for the HPV vaccine were done against a neurotoxic aluminum adjuvant, and four of the trials used another aluminum-containing vaccine as the comparison.
Recommended: How Plumbing (Not Vaccines) Eradicated Disease
Researchers from Mexico’s National Institute of Cardiology pored over 28 studies published through January 2017—16 randomized trials and 12 post-marketing case series—pertaining to the three human papillomavirus (HPV) vaccines currently on the market globally. In their July 2017 peer-reviewed report, the authors, Manuel Martínez-Lavin and Luis Amezcua-Guerra, uncovered evidence of numerous adverse events, including life-threatening injuries, permanent disabilities, hospitalizations and deaths, reported after vaccination with GlaxoSmithKline’s bivalent Cervarix vaccine and Merck’s quadrivalent or nine-valent HPV vaccines (Gardasil and Gardasil 9). Pharmaceutical company scientists routinely dismissed, minimized or concealed those injuries using statistical gimmicks and invalid comparisons designed to diminish their relative significance.
Of the 16 HPV vaccine randomized trials, only two used an inert saline placebo. Ten of the sixteen compared the HPV vaccine against a neurotoxic aluminum adjuvant, and four trials used an already-approved aluminum-containing vaccine as the comparison.
Scientific researchers view double-blind placebo trials as the gold standard for testing new drugs. To minimize bias, investigators randomly assign patients to either a “treatment” group or a “control” (placebo) group and then compare health outcomes. The standard practice is to compare a new drug against a “pharmacologically inert” placebo. To minimize opportunities for bias, neither patients nor researchers know which individuals received the drug and which the placebo. However, in clinical trials of the various HPV vaccines, pharmaceutical researchers avoided this kind of rigor and instead employed sleight-of-hand flimflams to mask the seriousness of vaccine injuries.
Using aluminum-containing placebos will obviously obscure comparison of the control groups. Those concerned with the HPV vaccine have argued that aluminum adjuvants are one of the most likely causes of adverse reactions. The placebos with aluminum caused adverse reactions among the “presumably unwitting patients who received them,” allowing the pharmaceutical companies to hide similar adverse reactions among people who received the vaccines. Although both placebo and study groups suffered numerous adverse events in these studies, there were minimal differences between the two groups. The similar adverse health reactions indicated to industry researchers and government regulators that the vaccines were not causing damage.